CAR-haNK cells targeting PD-L1 have demonstrated successful recognition and targeting of heterogeneous tumour cell populations, including both T cell-sensitive and T cell-resistant tumour cells, in an HNSCC mouse model, effectively overcoming immune resistance (170). This evidence concerns the gene CD274 and head and neck squamous cell carcinoma.